ADVERTISEMENT
3 /3 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Vaccines

Sanofi and Translate Bio add coronavirus to vaccine pact

by Michael McCoy
April 3, 2020 | APPEARED IN VOLUME 98, ISSUE 13

 

C&EN has made this story and all of its coverage of the coronavirus epidemic freely available during the outbreak to keep the public informed. To support our journalism, become a member of ACS or sign up for C&EN's weekly newsletter.

Sanofi’s vaccine business and Translate Bio will work together to develop an mRNA vaccine for the novel coronavirus. The collaboration will build on a 2018 pact in which Sanofi paid Translate $45 million to develop up to five mRNA vaccines for infectious diseases. For Sanofi, one of the world’s leading vaccine makers, the agreement complements a collaboration it formed in February with the US Biomedical Advanced Research and Development Authority to develop a cell-based vaccine against the virus.

X

Article:

This article has been sent to the following recipient:

Leave A Comment

*Required to comment